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Abstract
Background: Nuclear receptor subfamily 1, group D, member 1 (NR1D1) is a ligand-regulated nuclear receptor and
transcriptional factor. Although recent studies have implicated NR1D1 as a regulator of DNA repair and proliferation
in breast cancers, its potential as a therapeutic target for breast cancer has not been assessed in terms of clinical
outcomes. Thus, this study aims to analyze NR1D1 expression in breast cancer patients and to evaluate its potential
prognostic value.
Methods: NR1D1 expression was analyzed by immunohistochemistry using an anti-NR1D1 antibody in 694 breast
cancer samples. Survival analyses were performed using the Kaplan–Meier method with the log-rank test to
investigate the association of NR1D1 expression with clinical outcome.
Results: One hundred thirty-nine of these samples exhibited high NR1D1 expression, mostly in the nucleus of
breast cancer cells. NR1D1 expression correlated significantly with histological grade and estrogen receptor status.
Overall survival (OS) and disease-free survival (DFS) did not correlate significantly with NR1D1 expression in breast
cancer patients regardless of whether they had received chemotherapy. Subgroup analysis performed according to
molecular subtype of breast cancer showed a significant influence of high NR1D1 expression on OS (P = 0.002) and
DFS (P = 0.007) in patients with triple-negative breast cancer (TNBC) treated with chemotherapy.
Conclusions: High NR1D1 expression level had a favorable impact on OS and DFS in patients with TNBC treated
with chemotherapy. NR1D1 should be investigated further as a possible prognostic marker in TNBC patients
receiving chemotherapeutic treatment and as a target in the development of chemotherapeutic approaches to
treating TNBC.
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Background
Breast cancer is the most common cancer and the main
cause of cancer death in women worldwide [1]. It is a di-
verse and complex disease in terms of its histology and clin-
ical outcomes. In recent decades, significant advances have
been made in the molecular classification of breast cancer
and in treatment strategies including prognostic prediction.
The estrogen receptor (ER), progesterone receptor (PR),
and erb-b2 receptor tyrosine kinase 2 (ERBB2, also known
as human epidermal growth factor receptor 2 (HER2)), are
representative molecular biomarkers that distinguish breast
cancer subtypes, i.e., ER+/HER2−, ER+/HER2+, ER−/HER2+,
and ER−/HER2− [2]. Among these types of breast cancer,
ER−/HER2− breast cancer, also known as triple-negative
breast cancer (TNBC), because of the lack of ERα, PR, and
ERBB2 expression, is the most aggressive subtype with ad-
vanced histological grade and poor clinical outcome despite
appropriate treatment [3]. Because of the lack of appropri-
ate targets, there is no specific systemic treatment such as
endocrine therapy or HER2-targeted therapy for TNBC. At
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present, the basis of TNBC treatment is chemotherapy and
radiotherapy, which are associated with serious side effects.
Thus, the identification of new targets may provide benefits
in the treatment of women with TNBC by minimizing the
side effects.
One of the characteristics that make TNBC a more ag-
gressive and malignant subtype is a defective DNA dam-
age response system. For example, the incidence of the
germline breast cancer 1 (BRCA1) mutations is relatively
high in TNBC, and most BRCA1 mutation-associated
breast cancers are TNBC [3]. Similarly, defects in genes
related to DNA damage repair and genome mainten-
ance, such as the Fanconi Anemia Complementation
(FANC) group genes and 8-oxoguanine glycosylase 1,
have been reported in TNBCs [4, 5]. Given this strong
association between TNBC and the defects in genes in-
volved in DNA damage repair, understanding the DNA
damage response system may provide important prog-
nostic clues about TNBC.
Nuclear receptor subfamily 1, group D, member 1
(NR1D1), also known as REV-ERBα, is a ligand-
regulated nuclear receptor and transcriptional factor that
binds directly to specific DNA response elements and
represses target gene transcription [6]. NR1D1 regulates
diverse biological processes such as the circadian clocks,
cellular differentiation, metabolism, immune responses,
and behavior [7]. Several studies have reported that
NR1D1 is closely associated with the pathophysiology of
breast cancer. NR1D1 is located in the ERBB2 amplicon
region of chromosome 17q12–21 and is thought to be
part of the ERBB2 signature, which is associated with
poor clinical outcome in breast cancer [8, 9]. A synthetic
NR1D1 agonist, SR9011, suppresses the proliferation of
breast cancer cells regardless of the molecular subtype
of breast cancer [10].
We recently reported a newly identified function of
NR1D1, namely impairment of proper DNA repair. In
breast cancer cells, NR1D1 is recruited to DNA damage
sites and therein interacts with poly (ADP-ribose) poly-
merase 1 (PARP1) and subsequently inhibits the recruit-
ment of the DNA damage response complex including
SIRT6, pNBS1, and BRCA1 [11, 12]. Although NR1D1
may provide therapeutic options for improving the out-
come of chemotherapy in breast cancer patients, its po-
tential as a therapeutic target for breast cancer has not
been clearly assessed in clinical outcomes. Therefore, in
the present investigation, we performed a retrospective
study to investigate NR1D1 expression in breast cancer
patients and to evaluate its potential prognostic value.
Methods
Breast cancer tissue samples and patient information
Primary breast carcinoma samples were obtained from
Samsung Medical Center in Seoul, Korea, between 1995
and 2002. A total of 694 breast cancer patients were
retrospectively investigated. This breast cancer cohort
was from the Samsung Medical Center Breast Cancer
Biomarker Study (SMC-BCBS) [13]. The clinicopatho-
logical data included age, tumor characteristics such as
tumor size, lymph node (LN) involvement, LN metasta-
sis, American Joint Committee on Cancer (AJCC) stage,
and pathological stage. Adjuvant chemotherapy treat-
ment and survival data were obtained from medical re-
cords (Table 1). Cases were classified into breast cancer
subtypes, ER+/HER2−, ER+/HER2+, ER−/HER2+, and
TNBC. The protocol was approved by the ethical com-
mittees of the institutional review board (IRB) of the
Samsung Medical Center (IRB File No. 2017-11-078).
Immunohistochemical analysis
The immunohistochemical analysis was performed as
described previously [13]. Cores from breast cancer tis-
sues were obtained, and tissue microarray paraffin blocks
were generated. According to a routine protocol, the
sections were deparaffinized with xylene, hydrated in
serial dilutions of alcohol, and then were incubated in a
0.3% hydrogen peroxide solution for 15 min to neutralize
endogenous peroxidase activity. Next, the sections were
microwaved in citrate buffer for antigen retrieval. The
tissue sections were then incubated for 1 h at room
temperature with a primary antibody against NR1D1
(H00009572-M02, Novus Biologicals LCC, Littleton, CO,
USA) diluted to a final concentration of 1:1000. Subse-
quently, the tissue sections were washed and reacted
with an anti-mouse secondary antibody conjugated with
a horseradish peroxidase-labeled polymer (K4001, Dako,
Glostrup, Denmark) according to the manufacturers’ in-
structions. The tissue sections were rinsed, and stained
with liquid diaminobenzidine tetrahydrochloride, a high-
sensitivity substrate-chromogen system (K3468, DAKO,
Glostrup, Denmark) for 5 min. Counterstaining was per-
formed with Meyer’s hematoxylin. The immunohisto-
chemical staining was scored by pathologists based on
the intensity of staining and percentage of stained tumor
cells. The intensity of staining was scored as 0, negative;
1, weak; 2, moderate; and 3, strong. The percentage of
stained tumor cells was quantified and scored from 0 to
4: 0, negative or few; 1, < 25%; 2, 25–50%; 3, 50–75%;
and 4, > 75%. The percentage and the staining intensity
were then multiplied in order to generate the immuno-
reactive score for each of tumor specimens. Immunore-
active scores 0, 1, 2, 3, 4, 6, 8, and 9 were classified as
low NR1D1 expression, and score 12 was classified as
high NR1D1 expression. The numbers of specimens in
each immunohistochemical staining score were as
follows: 0, n = 3 (0.4%); 1, n = 23 (3.3%); 2, n = 69 (9.9%);
3, n = 62 (8.9%); 4, n = 86 (12.4%); 6, n = 129 (18.6%); 8,
n = 115 (16.6%); 9, n = 68 (9.8%); and 12, n = 139 (20.0%).
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Statistical analysis
Correlations between NR1D1 expression and clinico-
pathological characteristics were analyzed using the chi-
squared test. Overall survival (OS) was defined as the
time from the date of the primary surgery until the date
of death or the last follow-up. Disease-free survival
(DFS) was defined as the interval from the date of the
primary surgery to the date of recurrence, which indi-
cated locoregional recurrence, distant metastasis, or
death from any cause. The Kaplan–Meier method was
used for survival analysis, and the log-rank test was used
to estimate the associations between variables and sur-
vival. A univariable logistic regression model was used
to estimate the association of NR1D1 expression with
clinicopathological factors. The multivariable Cox re-
gression model was used to identify significant prognos-
tic factors among the clinicopathological factors and
NR1D1 expression. P values < 0.05 were considered as
significant. The statistical analyses were performed using
R software for statistical computing and graphics (http://
r-project.org).
Results
Characteristics of breast cancer patients according to
NR1D1 expression
We used immunohistochemistry to analyze NR1D1 ex-
pression in primary invasive breast cancer specimens. A
total of 694 patients who had informative immunohisto-
chemical results were included in this study. A represen-
tative tissue microarray stained for NR1D1 is shown in
Fig. 1. NR1D1 signals were found predominantly in the
nuclei of tumor cells in almost all samples. Immunohis-
tochemical staining scores were evaluated and classified
into low- and high-NR1D1 expression groups. In these
patients, the high-NR1D1 expression group score was 12
(n = 139) and the low-NR1D1 expression group score
was < 12 (n = 555). The clinicopathological characteris-
tics of the patients in the study cohort are summarized
in Table 1. Most of the patients (87.5%) were treated
with adjuvant chemotherapy. We estimated the correla-
tions of NR1D1 expression with clinicopathological
Table 1 Characteristics of breast cancer patients and their
NR1D1 expression level
Characteristics All patients Low NR1D1 High NR1D1
n = 694 n = 555 n = 139
No. (%) No. (%) No. (%) P valuea
Age at diagnosis (years) 0.199
≤ 50 420 60.5 343 61.8 77 55.4
> 50 274 39.5 212 38.2 62 44.6
Tumor size 0.077
T1 269 38.8 221 39.8 48 34.5
T2 378 54.5 292 56.2 86 61.9
T3 or T4 47 6.8 42 7.6 5 3.6
LN involvement 0.813
N0 354 51.0 288 51.9 66 47.5
N1 180 25.9 142 25.6 38 27.3
N2 85 12.2 67 12.1 18 12.9
N3 75 10.8 58 10.5 17 12.2
LN metastasis 0.404
Negative 354 51.0 288 51.9 66 47.5
Positive 340 49.0 267 48.1 73 52.5
AJCC stage 0.210
I 168 24.2 142 25.6 26 18.7
II 353 50.9 275 49.5 78 56.1
III 173 24.9 138 24.9 35 25.2
Histologic grade 0.011
1 76 11.0 69 12.4 7 5.0
2 246 35.4 201 36.2 45 32.4
3 323 46.5 246 44.3 77 55.4
Unknown 49 7.1 39 7.0 10 7.2
Estrogen receptor 0.021
Negative 282 40.6 213 38.4 69 49.6
Positive 411 59.2 341 61.4 70 50.4
Unknown 1 0.1 1 0.2 0 0.0
Progesterone receptor 0.393
Negative 379 54.6 298 53.7 81 58.3
Positive 314 45.2 256 46.1 58 41.7
Unknown 1 0.1 1 0.2 0 0.0
HER2 amplification 0.113
Negative 504 72.6 411 74.1 93 66.9
Positive 190 27.4 144 25.9 46 33.1
Breast cancer subtype 0.067
ER+/HER2− 334 48.1 281 50.6 53 38.1
ER+/HER2+ 97 14.0 74 13.3 23 16.5
ER−/HER2+ 92 13.3 69 12.4 23 16.5
TNBC (ER−/HER2−) 170 24.5 130 23.4 40 28.8
Undefined 1 0.1 1 0.2 0 0.0
Table 1 Characteristics of breast cancer patients and their
NR1D1 expression level (Continued)
Characteristics All patients Low NR1D1 High NR1D1
n = 694 n = 555 n = 139
No. (%) No. (%) No. (%) P valuea
Adjuvant chemotherapy 0.649
No 85 12.2 70 12.6 15 10.8
Yes 607 87.5 483 87.0 124 89.2
Unknown 2 0.3 2 0.4 0 0.0
aChi-square test, P values less than 0.05 are considered as significant changes
and marked in italics
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factors. NR1D1 expression correlated significantly with the
clinicopathological feature histological grade (P = 0.011)
and ERα status (P = 0.021). However, the correlations with
other parameters including adjuvant chemotherapy were
not significant (Table 1).
Survival analysis
The median follow-up times for OS and DFS were 10.3
years (range, 0.1–19.5 years) and 9.4 years (range, 0.1–19.5
years), respectively. During the follow-up, 28.6% (198 of
692) of the patients had recurrence and/or metastasis, and
23.9% (165 of 691) of the patients died. To investigate the
association of NR1D1 expression with clinical outcome,
survival analyses were performed using the Kaplan–Meier
method with the log-rank test. NR1D1 expression did
not correlate significantly with OS (P = 0.266) or DFS
(P = 0.387) in the breast cancer patients when all the
samples were included in the analysis. In breast cancer pa-
tients who received chemotherapy, the OS (P = 0.254) and
DFS (P = 0.243) did not differ significantly between groups
with low or high NR1D1 expression (Fig. 2). Subgroup
analyses according to molecular subtype of breast cancer
in patients treated with chemotherapy showed significant
influences of high NR1D1 expression on OS (P = 0.002)
and DFS (P = 0.007) in TNBC patients who received
chemotherapy (Fig. 3). These results suggest that high
NR1D1 expression had a favorable effect on OS and DFS
in TNBC patients treated with chemotherapy.
Fig. 1 Representative tissue microarray specimens stained for NR1D1. Immunoreactivity of representative tumor specimens is shown. Low and
high NR1D1 expression groups are defined in methods. The low NR1D1 expression ranges from immunoreactive scores 2 to 6 (left (P2xI1), middle
(P3xI1), and right (P3xI2)), and the high NR1D1 expression shows immunoreactive score 12 (all, P4xI3). P, percentage of stained tumor cells; I,
intensity of staining. Scale bar, 50 μm
Fig. 2 Association of NR1D1 expression with clinical outcome in breast cancer patients. Kaplan−Meier curves for OS and DFS according to NR1D1
expression in all breast cancer patients and in breast cancer patients receiving chemotherapy. Three or two patients without OS or DFS
information, respectively, were excluded from the analysis
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Prognostic analysis
Finally, we evaluated the association of NR1D1 expres-
sion with survival of TNBC patients who received
chemotherapy. In the univariate analysis, after chemo-
therapy, TNBC patients with high NR1D1 expression
had a greater probability of an improved OS and DFS
than did those with low NR1D1 expression. The factors
that predicted poor OS and DFS based on the univariate
analysis were larger tumor size, presence of LN involve-
ment, presence of LN metastasis, and advanced AJCC
stage in TNBC patients who received chemotherapy
(Table 2). To investigate this in depth, multivariate ana-
lysis was performed using Cox proportional hazard
models that included the factors that were significant or
marginal significant in the univariate analysis. The LN
involvement was excluded because of the redundancy to
LN metastasis and the small size of each subgroup. Im-
portantly, NR1D1 expression in TNBC patients who re-
ceived chemotherapy was significantly related to
improvements in OS and DFS in the multivariate ana-
lysis. Our results suggest that high NR1D1 expression is
associated with chemotherapeutic benefits and may be
an independent prognostic factor in patients with TNBC
(Table 3).
Discussion
Because of the lack of effective therapeutic targets, there
is no specific systemic treatment for TNBC. Currently,
TNBC treatment is typically based on chemotherapy and
radiotherapy. Despite the standard chemotherapy regi-
mens, TNBC patients respond differently to chemother-
apy, ranging from early remission to worse OS [14, 15].
Thus, identification of new biomarkers that can be used
to predict the response to conventional TNBC therapy
may be beneficial in the treatment of TNBC. In this
study, we found that high NR1D1 expression had a fa-
vorable impact on OS and DFS in patients with TNBC
treated with chemotherapy.
The DNA damage repair system is often defective in
TNBC patients, and monitoring of the DNA damage re-
sponse is an important prognostic clue. In TNBC patients,
the expression of DNA damage repair genes, such as xero-
derma pigmentosum complementation group F, FANC
group genes, PARP1, and RAD51, is associated with sensitiv-
ity to chemotherapy [16, 17]. We recently reported that
NR1D1 is a crucial component of the DNA damage re-
sponse, which may suggest that a high expression level of
NR1D1 increases the susceptibility of TNBC to DNA dam-
age induced by chemotherapeutic agents and ultimately lead-
ing to a better OS in TNBC patients [11]. Although our
previous study showed the inhibitory function of NR1D1 in
DNA repair in MCF7 cells (ER+/HER2−), this function was
also demonstrated in other molecular subtypes including
BT474 (ER+/HER2+) and MDA-MB-231 (TNBC) cells (data
not shown). Interestingly, however, the prognostic effect of
NR1D1 was exclusively found in TNBC and not in other
subtypes. One possible explanation could be that gene vari-
ables that confer susceptibility to chemotherapy may vary ac-
cording to molecular subtypes. For example, we showed
previously that relative expression of proliferation-related
and immune response-related genes, i.e., UBE2C, TOP2A,
RRM2, FOXM1, MK167, and BTN3A2, provided a predic-
tion value of adjuvant chemotherapy benefit for patients with
ER+/HER2− early breast cancer [18]. In ER−/HER+ subtype,
immune-related genes, i.e., BTN3A2, CD2, and TRBC1, and
invasiveness-related MMP11 were significantly associated
with a prognosis of this disease [19]. Thus, TNBCs could be
the most susceptible subtype that are being benefited from
Fig. 3 Prognostic significance of NR1D1 expression in TNBC patients treated with chemotherapy. Kaplan−Meier curves for OS and DFS according
to NR1D1 expression in molecular subtypes of breast cancer patients treated with chemotherapy. A patient with no subtype information was
excluded from the analysis
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the high intratumoral expression of NR1D1 after treatment
with DNA damaging chemotherapy.
Interestingly, several studies have reported that gen-
etic polymorphism of NR1D1 is associated with hu-
man diseases such as bipolar disorder and obesity
[20–23]. The variations were located mainly in the
first intron and in the 5′ untranslated region of
NR1D1, which may cause differential expression of
the gene, as shown in breast cancer patients. Thus,
the role of genetic variations in NR1D1 in the patho-
genesis and progression of breast cancer as well as
the chemotherapeutic responses may be an important
issue. More detailed analyses of the polymorphisms
and expression level of NR1D1 together with genomic
analysis for defects in DNA damage repair genes may
provide prediction value for clinical outcomes of adju-
vant chemotherapy in TNBC patients.
Because 10–20% of breast cancers are TNBC, identifi-
cation of new targets that could maximize the efficacy
but minimize the side effects of chemotherapy is an un-
met need [24]. Recently, small molecules that can modu-
late the activity of NR1D1 and their potential as
anticancer therapeutics were demonstrated [25]. SR9011,
a synthetic ligand of NR1D1, has been reported to in-
hibit the proliferation of various breast cancer cell lines
and to induce cell cycle arrest by suppressing cyclin A
[10]. Because NR1D1 increases DNA damage induced by
chemotherapeutic agents, the potential of combining
chemotherapy with ligands of NR1D1 may be a thera-
peutic option for a more effective approach. GSK4112, a
synthetic ligand of NR1D1, increased the chemosensitiv-
ity of breast cancer cells to doxorubicin [11]. In conclu-
sion, our study suggests that the expression level of
NR1D1 is both a prognostic marker for patients under
Table 2 Univariate analysis of OS and DFS in the TNBC patients treated with chemotherapy
Variables OS DFS
No. HR 95% CI P value No. HR 95% CI P value
NR1D1 expression
Low 122 1.00 123 1.00
High 37 0.09 0.01–0.63 0.016 37 0.17 0.04–0.73 0.017
Age at diagnosis
≤ 50 109 1.00 110 1.00
> 50 50 1.25 0.62–2.55 0.535 50 0.80 0.37–1.71 0.564
Tumor size
T1 55 1.00 56 1.00
T2 93 2.16 0.87–5.36 0.096 93 2.09 0.89–4.86 0.089
T3 or T4 11 7.63 2.46–23.70 < 0.001 11 4.58 1.34–15.68 0.015
LN involvement
N0 93 1.00 94 1.00
N1 36 1.03 0.36–2.94 0.950 36 0.77 0.28–2.10 0.607
N2 17 3.01 1.13–8.04 0.028 17 2.18 0.85–5.57 0.105
N3 13 15.26 6.46–36.05 < 0.001 13 7.99 3.23–19.79 < 0.001
LN Metastasis
No 93 1.00 94 1.00
Yes 66 2.79 1.37–5.66 0.005 66 1.77 0.90–3.46 0.099
AJCC stage
I 42 1.00 43 1.00
II 84 1.55 0.50–4.74 0.446 84 1.64 0.60–4.48 0.333
III 33 6.65 2.22–19.93 < 0.001 33 4.49 1.60–12.63 0.004
Histologic grade
1 3 – 3 –
2 31 1.00 31 1.00
3 99 1.86 0.64–5.39 0.251 100 1.57 0.60–4.14 0.358
Unknown 26 – – – 26 – – –
P values less than 0.05 are considered as significant changes and marked in italics
HR hazard ratio, CI confidential interval
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chemotherapeutic treatment and a target for the devel-
opment of chemotherapeutic approaches for the treat-
ment of TNBC.
Conclusions
Although NR1D1 implicates as a regulator of DNA re-
pair and proliferation in breast cancers, its potential as a
therapeutic target for breast cancer has not been
assessed in clinical outcomes. Our data showed that high
NR1D1 expression had a favorable impact on OS and
DFS in patients with TNBC treated with chemotherapy.
NR1D1 should be investigated further as a possible
prognostic marker in TNBC patients receiving chemo-
therapeutic treatment and as a target in the development
of chemotherapeutic approaches to treating TNBC.
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